EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease

Israa O Kashmoola, Shatha H Mohammad, Mohammad H Alsaaty

Global Cardiology Science and Practice · 29.06.2026 · 2026 (3)

DOI: 10.21542/gcsp.2026.20 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 29.06.2026. Verfasst von Israa O Kashmoola und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nineveh Health Directorate, Mosul, Nineveh Province, 41006, Iraq. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxidative stress and adipokine imbalance are important contributors to the pathogenesis of diabetic cardiovascular disease. The nuclear factor erythroid 2-related factor 2 (Nrf2) regulates antioxidant defense, while adipokines link metabolism and inflammation. Incretin-based therapies and PPARγ agonists may join on these pathways to provide cardiovascular protection beyond glycemic control. This review aims to investigate the current evidence on how incretin-based agents and PPARγ agonists regulate the adipokine-Nrf2 axis and their impact on cardiovascular outcomes in diabetes. A literature search was performed using PubMed, Google Scholar and Scopus to include reviews, experimental, clinical, and translational studies published in English until November 2025. Evidence indicates that incretin-based agents and PPARγ agonists synergistically activate Nrf2 and inhibit NF-kB signaling, leading to improved oxidative status and favorable adipokine levels. Increased adiponectin and omentin, and suppressed resistin, leptin and TNF-α contribute to reduced inflammation and enhanced vascular and myocardial protection. Collectively, combined activation of incretin and PPARγ pathways modulates the adipokine-Nrf2 axis, offering joined antioxidant and anti-inflammatory benefits that may reduce diabetic cardiovascular risk.

Autor:innen und Institutionen

  • Nineveh Health Directorate, Mosul, Nineveh Province, 41006, Iraq.
  • University of Mosul, College of Medicine, Department of Pharmacology, Mosul, Nineveh Province, 41002, Iraq.
  • University of Mosul, College of Medicine, Department of Medicine, Mosul, Nineveh Province, 41002, Iraq.

Zitieren

APA

Kashmoola, I. O., Mohammad, S. H., & Alsaaty, M. H. (2026). Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease. Global Cardiology Science and Practice, 2026(3). https://doi.org/10.21542/gcsp.2026.20

Vancouver

Kashmoola IO, Mohammad SH, Alsaaty MH. Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease. Global Cardiology Science and Practice. 2026;2026(3). doi:10.21542/gcsp.2026.20

BibTeX
@article{Kashmoola2026,
  author = {Kashmoola, Israa O and Mohammad, Shatha H and Alsaaty, Mohammad H},
  title = {Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease},
  journal = {Global Cardiology Science and Practice},
  year = {2026},
  volume = {2026},
  number = {3},
  doi = {10.21542/gcsp.2026.20}
}
Kostenlos starten →